Rezolute Inc (RZLT) Stock Analysis
Verdict: HOLD
Phase 3 clinical progress and aggressive insider buying signal a valuation catch-up, but the $70M annual burn necessitates flawless execution.
Investment score: 64/100
Analysis as of
Is Rezolute Inc stock worth reviewing? AI model thesis
Buy on clinical momentum and strong insider conviction.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 75/100 (weight 15%)
- Technical Momentum: 80/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 95/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Rezolute Inc opportunities and risks
What speaks for RZLT
- RZ358 Phase 3 Catalyst
What speaks against RZLT
- Binary Clinical Trial Failure
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RZLT | n/a | 0.0x | n/a | 0.0% | 0.0% | -18.3% |
| SGMT | n/a | 0.0x | n/a | 0.0% | 0.0% | -17.9% |
| ZURA | n/a | 0.0x | n/a | 0.0% | 0.0% | -28.7% |
| CATX | n/a | 478.9x | n/a | -358.1% | -19327.5% | -39.0% |
| XFOR | n/a | 42.6x | n/a | 79.4% | -1106.3% | -19.1% |
| EBS | n/a | 0.6x | 4.9x | 44.4% | -1.3% | 34.1% |
| Peer median | n/a | 0.6x | n/a | 0.0% | -1.3% | -19.1% |
Frequently asked questions about Rezolute Inc (RZLT)
Is RZLT stock a good investment?
The cached TradeMates AI model rates Rezolute Inc as HOLD with an investment score of 64/100. Buy on clinical momentum and strong insider conviction. This is algorithmic model output, not personal investment advice.
Is RZLT stock a buy?
The TradeMates model verdict for RZLT is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.